Tags

Type your tag names separated by a space and hit enter

Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi.
ChemMedChem. 2014 Feb; 9(2):371-82.C

Abstract

A significant improvement in the treatment of trypanosomiases has been achieved with the recent development of nifurtimox-eflornithine combination therapy (NECT). As an alternative to drug combinations and as a means to overcome most of the antitrypanosomatid drug discovery challenges, a multitarget drug design strategy has been envisaged. To begin testing this hypothesis, we designed and developed a series of quinone-coumarin hybrids against glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase (GAPDH/TR). These enzymes belong to metabolic pathways that are vital to Trypanosoma brucei and Trypanosoma cruzi, and have thus been considered promising drug targets. The synthesized molecules were characterized for their dual-target antitrypanosomal profile, both in enzyme assays and in in vitro parasite cultures. The merged derivative 2-{[3-(3-dimethylaminopropoxy)-2-oxo-2H-chromen-7-yl]oxy}anthracene-1,4-dione (10) showed an IC50 value of 5.4 μM against TbGAPDH and a concomitant Ki value of 2.32 μM against TcTR. Notably, 2-{4-[6-(2-dimethylaminoethoxy)-2-oxo-2H-chromen-3-yl]phenoxy}anthracene-1,4-dione (compound 6) displayed a remarkable EC50 value for T.brucei parasites (0.026 μM) combined with a very low cytotoxicity toward mammalian L6 cells (7.95 μM). This promising low toxicity of compound 6 might be at least partially due to the fact that it does not interfere with human glutathione reductase.

Authors+Show Affiliations

Department of Pharmacy & Biotechnology, University of Bologna, Via Belmeloro 6 / Via Irnerio 48, 40126 Bologna (Italy).No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24403089

Citation

Belluti, Federica, et al. "Toward the Development of Dual-targeted Glyceraldehyde-3-phosphate Dehydrogenase/trypanothione Reductase Inhibitors Against Trypanosoma Brucei and Trypanosoma Cruzi." ChemMedChem, vol. 9, no. 2, 2014, pp. 371-82.
Belluti F, Uliassi E, Veronesi G, et al. Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi. ChemMedChem. 2014;9(2):371-82.
Belluti, F., Uliassi, E., Veronesi, G., Bergamini, C., Kaiser, M., Brun, R., Viola, A., Fato, R., Michels, P. A., Krauth-Siegel, R. L., Cavalli, A., & Bolognesi, M. L. (2014). Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi. ChemMedChem, 9(2), 371-82. https://doi.org/10.1002/cmdc.201300399
Belluti F, et al. Toward the Development of Dual-targeted Glyceraldehyde-3-phosphate Dehydrogenase/trypanothione Reductase Inhibitors Against Trypanosoma Brucei and Trypanosoma Cruzi. ChemMedChem. 2014;9(2):371-82. PubMed PMID: 24403089.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi. AU - Belluti,Federica, AU - Uliassi,Elisa, AU - Veronesi,Giacomo, AU - Bergamini,Christian, AU - Kaiser,Marcel, AU - Brun,Reto, AU - Viola,Angelo, AU - Fato,Romana, AU - Michels,Paul A M, AU - Krauth-Siegel,R Luise, AU - Cavalli,Andrea, AU - Bolognesi,Maria Laura, Y1 - 2014/01/08/ PY - 2013/10/09/received PY - 2013/12/05/revised PY - 2014/1/10/entrez PY - 2014/1/10/pubmed PY - 2014/9/19/medline KW - framework combinations KW - glyceraldehyde-3-phosphate dehydrogenase KW - multitarget ligands KW - neglected tropical diseases KW - trypanothione reductase SP - 371 EP - 82 JF - ChemMedChem JO - ChemMedChem VL - 9 IS - 2 N2 - A significant improvement in the treatment of trypanosomiases has been achieved with the recent development of nifurtimox-eflornithine combination therapy (NECT). As an alternative to drug combinations and as a means to overcome most of the antitrypanosomatid drug discovery challenges, a multitarget drug design strategy has been envisaged. To begin testing this hypothesis, we designed and developed a series of quinone-coumarin hybrids against glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase (GAPDH/TR). These enzymes belong to metabolic pathways that are vital to Trypanosoma brucei and Trypanosoma cruzi, and have thus been considered promising drug targets. The synthesized molecules were characterized for their dual-target antitrypanosomal profile, both in enzyme assays and in in vitro parasite cultures. The merged derivative 2-{[3-(3-dimethylaminopropoxy)-2-oxo-2H-chromen-7-yl]oxy}anthracene-1,4-dione (10) showed an IC50 value of 5.4 μM against TbGAPDH and a concomitant Ki value of 2.32 μM against TcTR. Notably, 2-{4-[6-(2-dimethylaminoethoxy)-2-oxo-2H-chromen-3-yl]phenoxy}anthracene-1,4-dione (compound 6) displayed a remarkable EC50 value for T.brucei parasites (0.026 μM) combined with a very low cytotoxicity toward mammalian L6 cells (7.95 μM). This promising low toxicity of compound 6 might be at least partially due to the fact that it does not interfere with human glutathione reductase. SN - 1860-7187 UR - https://www.unboundmedicine.com/medline/citation/24403089/Toward_the_development_of_dual_targeted_glyceraldehyde_3_phosphate_dehydrogenase/trypanothione_reductase_inhibitors_against_Trypanosoma_brucei_and_Trypanosoma_cruzi_ L2 - https://doi.org/10.1002/cmdc.201300399 DB - PRIME DP - Unbound Medicine ER -